STANDARD BIOTOOLS INC
NASDAQ: LAB (Standard BioTools Inc.)
Kemas kini terakhir: semalam, 9:22PM1.07
0.00 (0.00%)
Penutupan Terdahulu | 1.07 |
Buka | 1.03 |
Jumlah Dagangan | 1,885,281 |
Purata Dagangan (3B) | 1,968,249 |
Modal Pasaran | 405,515,008 |
Harga / Jualan (P/S) | 2.39 |
Harga / Buku (P/B) | 0.950 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
Margin Keuntungan | -79.62% |
Margin Operasi (TTM) | -29.42% |
EPS Cair (TTM) | -0.520 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -14.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 118.03% |
Nisbah Semasa (MRQ) | 5.70 |
Aliran Tunai Operasi (OCF TTM) | -143.45 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -71.55 M |
Pulangan Atas Aset (ROA TTM) | -18.01% |
Pulangan Atas Ekuiti (ROE TTM) | -43.75% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Bercampur | Bercampur |
Medical Devices (Global) | Bercampur | Bercampur | |
Stok | Standard BioTools Inc. | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | NA |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 5.0 |
Osilator Teknikal | -0.5 |
Purata | 1.67 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 1.86% |
% Dimiliki oleh Institusi | 73.11% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Hollow Brook Wealth Management Llc | 30 Sep 2024 | 5,532,951 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
27 Feb 2025 | Pengumuman | Standard BioTools to Participate in Upcoming Investor Conferences |
26 Feb 2025 | Pengumuman | Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results |
12 Feb 2025 | Pengumuman | Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 |
13 Jan 2025 | Pengumuman | Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue |
08 Jan 2025 | Pengumuman | Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |